KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Capital Expenditures (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Capital Expenditures for 6 consecutive years, with $72000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 28.57% year-over-year to $72000.0, compared with a TTM value of $252000.0 through Dec 2025, down 10.32%, and an annual FY2025 reading of $252000.0, down 10.32% over the prior year.
  • Capital Expenditures was $72000.0 for Q4 2025 at Aurinia Pharmaceuticals, up from $65000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $3.5 million in Q2 2021 and bottomed at -$105000.0 in Q3 2023.
  • Average Capital Expenditures over 5 years is $280947.4, with a median of $85000.0 recorded in 2024.
  • Peak annual rise in Capital Expenditures hit 353.85% in 2023, while the deepest fall reached 362.5% in 2023.
  • Year by year, Capital Expenditures stood at $159000.0 in 2021, then fell by 15.72% to $134000.0 in 2022, then soared by 123.13% to $299000.0 in 2023, then tumbled by 81.27% to $56000.0 in 2024, then rose by 28.57% to $72000.0 in 2025.
  • Business Quant data shows Capital Expenditures for AUPH at $72000.0 in Q4 2025, $65000.0 in Q3 2025, and $98000.0 in Q2 2025.